ArticleInternational journal of cancer2025
Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.
Article in International journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities.British journal of cancer · 2026Article
- Review
- Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.International journal of cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Innate differences in the female and male immune systems and subgroup results from clinical trials have led researchers to hypothesize there could be sex-based disparities in the effectiveness of immune checkpoint inhibitors for anticancer treatment. This real-world study evaluated potential sex-based disparities in survival among non-small cell lung cancer (NSCLC) patients treated with pembrolizumab as monotherapy or in combination with chemotherapy. The population-based cohort included 1586 females and 1978 males diagnosed with advanced NSCLC in Norway, treated with first-line pembrolizumab (2017-2021) or platinum-based chemotherapy (2012-2016). Sex-based survival differences among pembrolizumab users, and survival benefits relative to chemotherapy users, were evaluated using lung-cancer specific survival adjusted for age, stage, histology, cardiovascular disease, education, and income. Results were presented for pembrolizumab mono- and combination therapy separately. We did not observe sex-based differences in survival among pembrolizumab monotherapy users. Among combination therapy users, females had higher survival than males (7 percentage points higher 18 months after treatment initiation); this effect persisted until the end of follow-up (36 months). When comparing the effect of pembrolizumab relative to chemotherapy, males derived a larger survival benefit from monotherapy than females. We did not observe any sex-based disparities in the survival benefit of combination therapy. Sex-based survival disparities in our study appeared to be associated with disparities in the effectiveness of chemotherapy, but could also indicate that pembrolizumab monotherapy is more effective for males. Framing the sex-based effectiveness of pembrolizumab as a survival difference versus benefit relative to chemotherapy affected whether a disparity was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.